Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NR5A1 | Q13285 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | RORA | P35398 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895091 | 1.00 | P2RX7 (0.38) | P2RX7MAPTL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL15871637 | 0.89 | P2RX7 (0.35) | P2RX7MAPTL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL13114614 | 0.86 | P2RX7 (0.41) | P2RX7MAPTL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL305866 | 0.85 | PARP1 (0.45) | P2RX7SMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL305867 | 0.85 | PARP1 (0.45) | P2RX7SMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL3005033 | 0.85 | PARP1 (0.45) | P2RX7SMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL3001598 | 0.81 | GAA (0.51) | P2RX7MAPTL3MBTL1ALDH1A1NR5A1 | |
| SCHEMBL307058 | 0.81 | GAA (0.51) | P2RX7MAPTL3MBTL1ALDH1A1NR5A1 | |
| SCHEMBL307057 | 0.81 | GAA (0.51) | P2RX7MAPTL3MBTL1ALDH1A1NR5A1 | |
| SCHEMBL306727 | 0.81 | P2RX7 (0.36) | P2RX7ALDH1A1NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | RENOVIS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118287-A1 | Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885MAPT 4534/4885L3MBTL1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.